Reshaping Neuromodulation™ with the MobiusHD® System

An endovascular device-based approach to help patients suffering from heart failure.

MobiusHD Enhances Natural Baroreflex Response.

Clinical symptoms addressed using established catheter-based techniques.

Baroreceptors and the baroreflex mechanism respond to changes in cardiac output by activating the sympathetic system, causing vasoconstriction and adjusting heart rate and blood pressure as needed to achieve homeostasis.  Over time, in heart failure, chronic impairment of the baroreflex results in overactive sympathetic drive and withdrawn parasympathetic activity thereby increasing the workload on the heart.

For symptomatic heart failure patients who have exhausted the benefits of medications, clinical relief may be provided from a new percutaneous, catheter-based therapy. The EVBA (endovascular baroreflex amplification) procedure using the unique MobiusHD device activates the body’s natural approach to restore autonomic balance and reduce the workload on the heart.

Learn More About EVBA Therapy

Clinical Research

Initial results of a feasibility clinical study of the EVBA approach in heart failure patients with reduced ejection fraction (HFrEF) have been reported.  These results show Improvements in several key clinical endpoints including patient-reported health status reports, functionality evaluations, echocardiographic findings, and biomarker testing with outcomes through 12 months of clinical follow-up.

Learn More About Our Clinical Evidence

Vascular Dynamics News

First German EVBA Procedure is Performed with New Heart Failure Therapy Approach

Learn More

Vascular Dynamics Completes $20 Million Equity Financing to Support Further Clinical Evaluations of MobiusHD Device

Learn More

Vascular Dynamics’ Early Clinical Results for Novel Heart Failure Treatment Show Promise as Stan Rabinovich is Named to Board of Directors

Learn More